0 0 0 0 0.00118996105581999 0.0060579835569018 0.0060579835569018 0.0060579835569018
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]

Biogen Inc. (BIIB)  More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
through the end of the decade, and CEO Christopher Viehbacher says the company is entering a "whole new era of growth" even as it has cut R&D spending by about 25% over three years to reallocate resources toward launch and medical activities. Leqembi's complex launch is being simplified via approved blood-based diagnostics (raising appropriate-treatment yield from ~50% to ~70%), a subcutaneous maintenance form already approved and a subcutaneous induction under priority review (decision expected May 24), with Part D coverage timing that could affect availability in 2027. Biogen will be selective on M&A , focusing on assets with nearer-term launch potential because replacing $1 billion of after-tax profit could require $15–$20 billion in deals; near-term growth is expected to come from recent launches (Leqembi, QALSODY, ZURZUVAE, SKYCLARYS) while legacy MS products face continued competitive erosion and a mid-single-digit revenue decline is guided for 2026. Interested in Biogen I [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]

Biogen Inc.  (BIIB) 
More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
through the end of the decade, and CEO Christopher Viehbacher says the company is entering a "whole new era of growth" even as it has cut R&D spending by about 25% over three years to reallocate resources toward launch and medical activities. Leqembi's complex launch is being simplified via approved blood-based diagnostics (raising appropriate-treatment yield from ~50% to ~70%), a subcutaneous maintenance form already approved and a subcutaneous induction under priority review (decision expected May 24), with Part D coverage timing that could affect availability in 2027. Biogen will be selective on M&A , focusing on assets with nearer-term launch potential because replacing $1 billion of after-tax profit could require $15–$20 billion in deals; near-term growth is expected to come from recent launches (Leqembi, QALSODY, ZURZUVAE, SKYCLARYS) while legacy MS products face continued competitive erosion and a mid-single-digit revenue decline is guided for 2026. Interested in Biogen I [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS